OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

Jun 16 2010

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC). An updated safety and outcome analysis from this trial was recently presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing that trends towards improved outcomes were observed in response rate, progression-free survival and overall survival rates in the study arm (ZYBRESTAT combined with bevacizumab and carboplatin/paclitaxel chemotherapy) as compared with the control arm (bevacizumab and chemotherapy) of the trial. The combination regimen including ZYBRESTAT was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. OXiGENE anticipates that further data from the trial will be available later in 2010.

"We continue to be encouraged by the growing body of data showing that ZYBRESTAT has potential as an important cancer treatment based on its unique vascular disrupting mechanism of action and excellent combinability with other treatment modalities, including anti-angiogenic agents," said Peter Langecker, M.D., Chief Executive Officer at OXiGENE. "We look forward to presenting a more complete analysis of the FALCON trial later in 2010 at a scientific meeting. If the encouraging positive trends in terms of progression free survival and overall survival that we presented at ASCO are maintained, they will underscore ZYBRESTAT's utility in non-small cell lung cancer and potentially pave the way toward embarking upon a registration pathway. We appreciate the positive response to our data from the oncology community and plan to continue efforts to find a partner for later-stage development."